Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?

The hormone receptor-positive, HER2-positive (HR+/HER2+) breast cancer subtype is a distinct clinical entity from hormone receptor-negative, HER2-positive (HR−/HER2+) breast cancer. Moreover, there is heterogeneity among HR+/HER2+ tumors. The main oncogenic driver may vary among HR+/HER2+ patients with different subsets of patients showing differential sensitivity to HER2 and hormone receptor pathway targeting. (Palmer and Sorger, PMID 29245013) While HR+/HER2+ tumors may initially respond to HE...

As opposed to combining hormonal therapies with HER2-targeted therapies that are intended to block signaling through the HER2 pathway, such as trastuzumab or the combination of trastuzumab and pertuzumab, whether administered in place of or after a course of chemotherapy combined with those HER2-targeted therapies, I have not combined hormonal therapies with the HER2-targeted antibody-drug conjugates (ADCs), whose mechanism of action is to use the surface HER receptor to gain access to the cance...